Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Continued momentum expected in 2017 with several programs anticipating clinical trial results this year, including two Phase 3 programs Phase 2 placebo-controlled study of SAGE-217 in major depressive disorder expected to begin in 1H 2017 First NMDA candidate, SAGE-718, planned to enter Phase 1
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday,
View HTML
Toggle Summary Sage Therapeutics Not in M&A Discussions: STATEMENT
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE) - On February 16, 2017 , Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD). During the course of the interview, Dr. Jonas acknowledged the industry's interest in the MDD
View HTML
Toggle Summary Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder
Open-label Pilot Study of Once Daily , Orally Administered Molecule Demonstrates Positive Signal of Activity and Tolerability CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central
View HTML
Toggle Summary Sage Therapeutics to Participate in Upcoming February Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will participate in the following upcoming conferences: SunTrust
View HTML
Toggle Summary Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company is scheduled to present at the J.P.
View HTML
Toggle Summary Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will participate in
View HTML
Toggle Summary Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in major depressive disorder and trial sites open for Phase 2 trial of SAGE-217 in postpartum depression Four Phase 2 clinical programs now underway for SAGE-217 in mood and movement disorders CAMBRIDGE, Mass.
View HTML
Toggle Summary Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Movement Disorders
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in Parkinson's disease Trial sites are open and screening patients for the Phase 2a trial in essential tremor; patients expected to be dosed imminently CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ:SAGE), a
View HTML
Toggle Summary Sage Therapeutics to Webcast R&D Day on December 13, 2016
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will webcast its R&D Day on Tuesday, December 13, 2016 from 12:30
View HTML